Literature DB >> 25079876

Chimerism versus minimal residual disease monitoring after allogeneic transplantation--when do we act and will intervention improve outcomes?

Michael A Pulsipher1.   

Abstract

Mesh:

Substances:

Year:  2014        PMID: 25079876     DOI: 10.1016/j.bbmt.2014.07.026

Source DB:  PubMed          Journal:  Biol Blood Marrow Transplant        ISSN: 1083-8791            Impact factor:   5.742


× No keyword cloud information.
  1 in total

1.  Minimal residual disease assessment by next-generation sequencing. Better tools to gaze into the crystal ball?

Authors:  A Balduzzi
Journal:  Bone Marrow Transplant       Date:  2017-06-05       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.